139 related articles for article (PubMed ID: 18801083)
1. Expression of E- and N-cadherin and clinicopathology in hepatocellular carcinoma.
Cho SB; Lee KH; Lee JH; Park SY; Lee WS; Park CH; Kim HS; Choi SK; Rew JS
Pathol Int; 2008 Oct; 58(10):635-42. PubMed ID: 18801083
[TBL] [Abstract][Full Text] [Related]
2. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma.
Korita PV; Wakai T; Shirai Y; Matsuda Y; Sakata J; Cui X; Ajioka Y; Hatakeyama K
Hum Pathol; 2008 Dec; 39(12):1777-83. PubMed ID: 18701136
[TBL] [Abstract][Full Text] [Related]
4. [Expression patterns of E-cadherin and beta-catenin according to clinicopathological characteristics of hepatocellular carcinoma].
Bae SH; Jung ES; Park YM; Jang JW; Choi JY; Cho SH; Yoon SK; Ahn BM; Cha SB; Chung KW; Sun HS; Park DH; Kim BK; Kim DG
Taehan Kan Hakhoe Chi; 2002 Sep; 8(3):297-303. PubMed ID: 12499787
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of E-cadherin, CD34 in the patients with hepatocellular carcinoma].
Wu LQ; Lu Y; Lu HJ; Zhang B; Yang JY; Ma X
Zhonghua Wai Ke Za Zhi; 2006 Jun; 44(11):774-7. PubMed ID: 16836930
[TBL] [Abstract][Full Text] [Related]
6. Relation among p130Cas, E-cadherin and beta-catenin expression, clinicopathologic significance and prognosis in human hepatocellular carcinoma.
Guo C; Liu QG; Yang W; Zhang ZL; Yao YM
Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):490-6. PubMed ID: 18842495
[TBL] [Abstract][Full Text] [Related]
7. Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma.
Iso Y; Sawada T; Okada T; Kubota K
J Surg Oncol; 2005 Dec; 92(4):304-11. PubMed ID: 16299806
[TBL] [Abstract][Full Text] [Related]
8. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma.
Huang GT; Lee HS; Chen CH; Sheu JC; Chiou LL; Chen DS
Hepatogastroenterology; 1999; 46(27):1923-7. PubMed ID: 10430370
[TBL] [Abstract][Full Text] [Related]
9. Anti-apoptotic N-cadherin signaling and its prognostic implication in human hepatocellular carcinomas.
Gwak GY; Yoon JH; Yu SJ; Park SC; Jang JJ; Lee KB; Lee SH; Lee SM; Shin CS; Suh KS; Lee HS
Oncol Rep; 2006 May; 15(5):1117-23. PubMed ID: 16596172
[TBL] [Abstract][Full Text] [Related]
10. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
11. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma.
Higashi Y; Suzuki S; Sakaguchi T; Nakamura T; Baba S; Reinecker HC; Nakamura S; Konno H
J Surg Res; 2007 May; 139(1):68-76. PubMed ID: 17270214
[TBL] [Abstract][Full Text] [Related]
12. [Expression and prognostic value of Polo-like kinase 1, E-cadherin in the patients with hepatocellular carcinoma].
Chen XJ; Wu LM; Xu XB; Feng XW; Xie HY; Zhang M; Shen Y; Wang WL; Liang TB; Zheng SS
Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1354-8. PubMed ID: 18241575
[TBL] [Abstract][Full Text] [Related]
13. No association exists between E-cadherin gene polymorphism and tumor recurrence in patients with hepatocellular carcinoma after transplantation.
Li XD; Wu LM; Xie HY; Xu X; Zhou L; Liang TB; Wang WL; Shen Y; Zhang M; Zheng SS
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):254-8. PubMed ID: 17548247
[TBL] [Abstract][Full Text] [Related]
14. Significance of the serum level of soluble E-cadherin in patients with HCC.
Soyama A; Eguchi S; Takatsuki M; Kawashita Y; Hidaka M; Tokai H; Nagayoshi S; Mochizuki S; Matsumoto S; Hamasaki K; Tajima Y; Kanematsu T
Hepatogastroenterology; 2008; 55(85):1390-3. PubMed ID: 18795696
[TBL] [Abstract][Full Text] [Related]
15. Two pathologic types of hepatocellular carcinoma with lymph node metastasis with distinct prognosis on the basis of CK19 expression in tumor.
Zhuang PY; Zhang JB; Zhu XD; Zhang W; Wu WZ; Tan YS; Hou J; Tang ZY; Qin LX; Sun HC
Cancer; 2008 Jun; 112(12):2740-8. PubMed ID: 18412155
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PRL-3 expression, and its correlation with angiogenesis and invasion in hepatocellular carcinoma.
Zhao WB; Li Y; Liu X; Zhang LY; Wang X
Int J Mol Med; 2008 Aug; 22(2):187-92. PubMed ID: 18636172
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter.
Lim SO; Gu JM; Kim MS; Kim HS; Park YN; Park CK; Cho JW; Park YM; Jung G
Gastroenterology; 2008 Dec; 135(6):2128-40, 2140.e1-8. PubMed ID: 18801366
[TBL] [Abstract][Full Text] [Related]
18. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma.
Wang XQ; Luk JM; Leung PP; Wong BW; Stanbridge EJ; Fan ST
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):483-9. PubMed ID: 15701831
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
20. TIP30 mutant derived from hepatocellular carcinoma specimens promotes growth of HepG2 cells through up-regulation of N-cadherin.
Jiang C; Pecha J; Hoshino I; Ankrapp D; Xiao H
Cancer Res; 2007 Apr; 67(8):3574-82. PubMed ID: 17440068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
